Dr. Tomáš Horák

Dr. Tomáš Horák is a senior neurologist at the General University Hospital Prague (VFN), affiliated with Charles University's First Faculty of Medicine, the Czech Republic's foremost academic medical center. With over 21 years of clinical neurology practice, he is recognized as one of the country's leading experts in stroke management and multiple sclerosis.

Dr. Horák completed a research fellowship in neuroimmunology at the University of Vienna's Department of Neurology, where he deepened his understanding of the pathophysiology of MS and developed expertise in advanced disease-modifying therapies. He returned to Prague where he established the MS Center at the General University Hospital.

He leads a multidisciplinary stroke team, coordinating time-sensitive thrombolysis and mechanical thrombectomy decisions in acute stroke cases. His commitment to evidence-based practice and continuous medical education has made him a key figure in Czech neurology training.

Dr. Horák is a sought-after speaker at national and international neurology conferences and has been instrumental in introducing several advanced MS therapies to Czech clinical practice in alignment with EAN guidelines.

Dr. Horák obtained his MD from Charles University First Faculty of Medicine in Prague in 2000. He completed his neurology residency at the General University Hospital Prague and subsequently undertook a neuroimmunology fellowship at the Department of Neurology, University of Vienna (2005–2007). He was awarded his PhD in 2009 for research on T-cell mechanisms in multiple sclerosis. He holds certification from the European Board of Neurology and is a member of the European Academy of Neurology (EAN).

Dr. Horák's clinical expertise encompasses the full spectrum of neurological disease with particular depth in stroke medicine and multiple sclerosis. In stroke care, he leads acute management decisions including intravenous thrombolysis and coordinates with interventional neuroradiologists for mechanical thrombectomy. In MS, he manages all disease subtypes and prescribes the full range of approved disease-modifying therapies including natalizumab, alemtuzumab, ocrelizumab, and cladribine. He also treats epilepsy, Parkinson's disease, and migraine, and performs electrodiagnostic studies including EEG and EMG.

Dr. Horák has authored over 50 peer-reviewed publications in journals including Multiple Sclerosis Journal and the European Journal of Neurology. His research focuses on neuroimmunological mechanisms in MS, outcome prediction after acute ischemic stroke, and real-world effectiveness of MS disease-modifying therapies. He is a principal investigator in several EAN-affiliated research projects and participates in the Czech MS registry.

Dr. Horák speaks Czech, English, and German and has significant experience treating international patients seeking neurology consultations and second opinions in Prague. The General University Hospital Prague has an international patient reception that assists with appointments and medical record review. Video consultations are available for MS monitoring and follow-up, and detailed English-language summaries of diagnosis and treatment plans are provided. Prague's central European location and well-developed transport connections make it convenient for international neurological patients.

Dr. Horák received the Czech Neurological Society Award for Research Excellence in 2016. He was recognized by the European Academy of Neurology for his contribution to MS center development in Central Europe. He received the General University Hospital Prague's Medical Excellence Award in 2022 for his leadership in establishing the hospital's stroke unit to European Stroke Organisation (ESO) standards.